Compendium of Cancer Genome Aberrations

HAEM5:ALK-negative anaplastic large cell lymphoma: Difference between revisions

(View all pending changes)
[pending revision][pending revision]
← Older editNewer edit →
VisualWikitext
Line 60: Line 60:
|-
|-
|'''Laboratory Findings'''
|'''Laboratory Findings'''
|Not specific  
|Not specific
|}
|}


Line 158: Line 158:
|No
|No
|
|
* <nowiki>*</nowiki> These rearrangements are considered mutually exclusive; however, a single case with both ''DUSP22'' and ''TP63'' rearrangement has been described<ref name=":11" />. Can also be seen in a fraction of other PTCL.
*<nowiki>*</nowiki> These rearrangements are considered mutually exclusive; however, a single case with both ''DUSP22'' and ''TP63'' rearrangement has been described<ref name=":11" />. Can also be seen in a fraction of other PTCL.
* 5-year overall survival > 90%
*5-year overall survival > 90%
* '''Therapeutic Implications'''
*'''Therapeutic Implications'''
**Multi-agent chemotherapy (CHOEP or CHOP-based) as first-line, with or without radiotherapy of involved site
**Multi-agent chemotherapy (CHOEP or CHOP-based) as first-line, with or without radiotherapy of involved site
**High dose chemotherapy and autologous stem cell transplantation for remission
**High dose chemotherapy and autologous stem cell transplantation for remission
Line 176: Line 176:
|No
|No
|
|
* *See t(6;7) notes
*<nowiki>*See t(6;7) notes</nowiki>
* 5-year overall survival > 17%
*5-year overall survival > 17%
|-
|-
|t(10;19)(q24;p13)
|t(10;19)(q24;p13)
Line 187: Line 187:
|No
|No
|
|
* 5-year overall survival 42% for cases lacking all DUSP22, TP63 and ALK rearrangements<ref name=":0" /><ref name=":15" />
*5-year overall survival 42% for cases lacking all DUSP22, TP63 and ALK rearrangements<ref name=":0" /><ref name=":15" />
|-
|-
|t(1;19)(p34;p13)
|t(1;19)(p34;p13)
Line 284: Line 284:
|No
|No
|No
|No
|Prevalence 30%
|
* Prevalence 30%
* Numerous genes affected
|-
|-
|6p
|Gain
|25.3
|
|
|EXAMPLE Gain
|EXAMPLE
chr8:1-145,138,636 [hg38]
|EXAMPLE
chr8
|No
|No
|No
|No
|No
|No
|EXAMPLE
|
 
* Prevalence 30%
Common recurrent secondary finding for t(8;21) (add reference).
* Gene affected: ''DUSP22''
|-
|8q
|Gain
|24.22
|
|No
|No
|No
|
* Prevalence 16-23%
* Genes affected: NDRG1, ''PHF20L1, SLA, ST3GAL1, TG, WISP1''
|-
|1p
|Loss
|13.3-p12
36.33-36.32
|
|No
|No
|No
|
* Prevalence 19-26%
|-
|'''6q'''
|'''Loss > CN-LOH'''
|21
|
|No
|No
|No
|
* Prevalence 35%
* Genes affected: '''''PRDM1''', ATG5''
|-
|10p
|Loss
|11.23-p11.22
|
|No
|No
|No
|
* Prevalence 23%
|-
|13q
|Loss
|32.3-q33.3
|
|No
|No
|No
|
* Prevalence 23%
* Genes affected: ''CDC16, CUL4A,FOXO1A, BRCA2, LHFP, LCP1''
|-
|16q
|Loss
|23.2
|
|No
|No
|No
|
* Prevalence 29%
* Genes affected: ''MAF, WWOX''
|-
|17p
|Loss
|'''13.3-p12'''
|
|No
|Yes?**
|No
|
* Prevalence: 42%
* ''Gene affected: TP53''
|}
|}


Retrieved from "https://test.ccga.io/index.php/HAEM5:ALK-negative_anaplastic_large_cell_lymphoma"